靶向TLR9的STAT3反义寡脱氧核苷酸联合PD1免疫检查点阻断的多模式胶质瘤免疫治疗
该研究描述了一种细胞选择性双链STAT3反义寡核苷酸(CpG-STAT3dsASO),可靶向人/小鼠胶质瘤细胞及胶质瘤相关巨噬细胞(GAM)而不靶向T细胞。在免疫健全或免疫缺陷小鼠中评估其安全性和对原位GBM的疗效,结果显示颅内/瘤内注射耐受良好并延缓肿瘤进展;单药无治愈效果,但与系统性PD1抑制联合可使GL261及免疫治疗耐药的QPP8胶质瘤消退并使多数小鼠长期生存。
要点
- CpG-STAT3dsASO颅内/瘤内注射耐受良好,可延缓人U251异种移植及小鼠GL261或神经细胞来源QPP8胶质瘤进展。
- 与单链寡核苷酸不同,局部给予CpG-STAT3dsASO在治疗剂量范围内未在免疫健全小鼠触发I型IFN依赖性神经毒性。
- CpG-STAT3dsASO单药无治愈效果,仅招募有限数量且多为耗竭状态的效应CD8+ T细胞。
核心结论
- 结果提示,使用CpG-STAT3dsASO破坏GAM依赖性免疫逃逸、从而恢复对PD1阻断的敏感性并促进T细胞介导的抗肿瘤免疫反应,为GBM免疫治疗提供了依据。
研究设计与样本
- 研究描述了一种细胞选择性双链STAT3反义寡核苷酸(CpG-STAT3dsASO),靶向人/小鼠胶质瘤细胞和GAM而不靶向T细胞。
- 在免疫健全或免疫缺陷小鼠中评估该寡核苷酸对原位GBM的安全性和疗效。
主要发现
- 颅内/瘤内注射CpG-STAT3dsASO耐受良好,并延缓人U251 GBM异种移植及小鼠GL261或神经细胞来源QPP8胶质瘤进展。
- 与单链寡核苷酸不同,局部给予CpG-STAT3dsASO在治疗剂量范围内未在免疫健全小鼠触发I型IFN依赖性神经毒性。
- CpG-STAT3dsASO激活瘤内GAM(如树突状细胞、巨噬细胞和小胶质细胞),扩增CD4+ Th1细胞并减少TREG数量。
- CpG-STAT3dsASO单药无治愈效果,仅招募有限数量且多为耗竭状态的效应CD8+ T细胞。
- CpG-STAT3dsASO联合系统性PD1抑制可使GL261及免疫治疗耐药的QPP8胶质瘤消退,并使多数小鼠长期生存;联合治疗增强CD8+效应T细胞活性,空间转录组学显示其促进瘤内与活化CD4+ Th1细胞及活化巨噬细胞的相互作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic resistance in glioblastoma (GBM) is multifactorial and results from genetic heterogeneity, the immunoprivileged localization, and the potently tolerogenic microenvironment. Signal transducer and activator of transcription 3 (STAT3) plays a key role in both glioma cell survival and immune evasion, reinforcing GBM resistance. METHODS: Here, we describe a new cell-selective and double-stranded STAT3 antisense oligonucleotide (CpG-STAT3dsASO) for targeting human/mouse glioma cells and GAMs but not T cells. The oligonucleotide safety and efficacy against orthotopic GBM was assessed in immunocompetent or immunodeficient mice. RESULTS: CpG-STAT3dsASO injected intracranially/intratumorally was well-tolerated and reduced progression of human U251 GBM xenotransplants and mouse GL261 or neural cell-derived QPP8 gliomas. Unlike the single-stranded oligonucleotide, local CpG-STAT3dsASO administration did not trigger type-I IFN-dependent neurotoxicities in immunocompetent mice within the therapeutic dose range. CpG-STAT3dsASO activated intratumoral GAMs, such as dendritic cells, macrophages and microglia, thereby expanding CD4+ Th1 cells while reducing TREG numbers. CpG-STAT3dsASO monotherapy did not have curative effects as it led to recruitment of only limited numbers of mostly exhausted effector CD8+ T cells. However, when combined with systemic PD1 inhibition, CpG-STAT3dsASO/anti-PD1 treatments caused regression of GL261 as well as immunotherapy-resistant QPP8 gliomas and resulted in long-term survival of the majority of mice. The combination treatment boosted CD8+ effector T-cell activity, while promoting their intratumoral interaction with activated CD4+ Th1 cells and activated macrophages as indicated by spatial transcriptomics. CONCLUSIONS: Our results suggest rationale for GBM immunotherapy using CpG-STAT3dsASO to disrupt GAMs-dependent immune evasion, thereby restoring sensitivity to PD1 blockade and facilitating T-cell-mediated antitumor immune responses.
引用
- Hung CY, Kang EY, Jacek K, et al. Multimodal glioma immunotherapy combining TLR9-targeted STAT3 antisense oligodeoxynucleotides with PD1 immune checkpoint blockade. Neuro Oncol. 2025. PMID: 40214214. doi:10.1093/neuonc/noaf099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。